Table 1 Extensively studied biomarkers of oxidative stress in patients with leukemia
Biomarkers | Clinical Significance | Pioneer(S) |
|---|---|---|
MDA,TAC | To determine the involvement of OS in AML development and implicate biomarkers of OS in disease diagnosis and prognosis | Tsamesidis et al. 2019 |
PC,TBARS,LOOH | To evaluate and quantify products of protein carbonylation and lipid peroxidation as valuable indicators for OS and disease progression in CML | Singh et al. 2009 |
MDA | To estimate MDA concentration as a marker of OS in AML patients receiving treatment | A. Hlavackova et al. 2019 |
TBARS, PC | To determine oxidative damage from increased OS and decreased antioxidant defense in ALL patients | Battisti et al. 2008 |